Advanced searches left 3/3

Type 2 Diabetes - Wiley Online Library

Summarized by Plex Scholar
Last Updated: 09 November 2022

* If you want to update the article please login/register

A randomized clinical trial of beetroot juice consumption on inflammatory markers and oxidative stress in patients with type 2 diabetes

Both initiation and progression of diabetes are important underlying factors for diabetes onset and progression, as well as the emergence of long-term diabetes mellitus in patients with type 2 diabetes mellitus. This research was intended to investigate the effect of beetroot juice intake on oxidative stress and inflammatory markers in patients with T2DM. 52 patients with T2DM were randomly assigned to either the targeted BJ or the control group in this trial. Each day, the BJ group received 12 ml concentrated BJ, whereas the control group had no involvement. Following a 12u2010week intervention, BJ reduced IL-u20106, TNFu2013, u03b1, and NFu2013bbaB; BJ reduced ILu20106, TNFu2010u2013. u2013b1, and NFu2010u03b1, a 2010u03b1, and NFu2013. u03b1 u03b1, BJ decreased u2010u2010u2010u2010u10b1 u2010u2010u2010u2011au01b1 u03b1u1010u2010u2010u03b1 u03b1 u2013u2013u20b1u2013u03b1 u03b1u03b1 u03b1 u2013aBu03b1u03b1u03b1u2010u03b1u2013u2010u2010u03b1u03b1u201u03b1u BJ daily intake, according to a baseline, could not change oxidative stress and inflammatory markers except for TNFu2010u03b1 compared to the baseline.

Source link: https://onlinelibrary.wiley.com/doi/10.1111/1750-3841.16365


The challenges and pitfalls of incorporating evidence from cardiovascular outcomes trials in health economic modeling of type 2 diabetes

In recent years, the clinical evidence base for evaluating modern type 2 diabetes treatment has expanded tremendously, with a slew of safe treatment options available. As new diabetes models were established prior to the conduct of the CVOTs, there have been growing calls to include these results in the long-term analysis of type 2 diabetes interventions, and therefore risk equations were drawn in the absence of these results. Analyses that use CVOT data inappropriately can dilute hard evidence from head-to-u2010head clinical trials, blurring healthcare decision making and blur healthcare decision making. Calibration of existing models may be an attempt to incorporate CVOT results into diabetes modeling, but it does not provide a reliable comparison of one intervention versus placebo based on a single CVOT. Model design should aim to use patient registry data from CVOTs to create novel risk equations that can help model current therapies for type 2 diabetes.

Source link: https://onlinelibrary.wiley.com/doi/10.1111/dom.14917


Type 2 diabetes mellitus stimulated pulmonary vascular inflammation and exosome biogenesis in rats

Type 2 Diabetes Mellitus has been reported to influence numerous cell types' paracrine function. We investigated the effect of T2M on exosome biogenesis in rat pulmonary tissue here. Rats were given a high-u2010fat diet regimen and a single low dose of Streptozocin to mimic the T2DMu2010like condition. Using immunohistochemistry staining, vascular cell adhesion molecule 1 levels were determined in addition to histological examination. Intrinical CD63 levels were determined using western blot analysis. When compared to the normal conditions, IHC staining increased VCAMu20101 expression in the diabetic lungs. Likewise, we detected the induction of ILu20101b2, exosome-u2010-related genes Alix and Rab27b under diabetic conditions compared to the control group. Along with these changes, CD63 and AChE production was stimulated on the initiation of T2DM, indicating an increase in exosome biogenesis. In rats pulmonary tissue impacted by T2DM, latest results show the initiation of exosome biogenesis.

Source link: https://onlinelibrary.wiley.com/doi/10.1002/cbf.3764


A Multi‐center, Randomized, Double‐Blinded, Parallel, Active and Placebo‐Controlled Phase 3 Clinical Study of the glucokinase activator PB‐201 in Treatment‐naive Patients with Type 2 Diabetes Mellitus: A Study Protocol

Glucokinase activators, an emerging new class of therapy for Type 2 Diabetes Mellitus is Glucokinase activators. Herein, we present the study design and rationale of using PBu2010201, a partial GKA, in a phase 3 research investigating its effectiveness and safety in the Chinese population. This is the first GKA phase 3 trial with a scheme that included an active control arm as opposed to a placebo control arm.

Source link: https://onlinelibrary.wiley.com/doi/10.1111/dom.14909

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions